{
    "nctId": "NCT03084939",
    "briefTitle": "Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab Emtansine Versus Lapatinib Plus Capecitabine in Chinese Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 351,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged \\>/= 18 years\n* Prospective centrally assessed HER2-positive disease (i.e., immunohistochemistry \\[IHC\\] 3+ and/or gene amplified \\[HER2 to Chromosome 17 \\[CEP 17\\] ratio \\>/= 2\\]) by in situ hybridization (ISH) through use of archival paraffin-embedded tumor tissue\n* Histologically or cytologically confirmed invasive breast cancer (BC): incurable, unresectable LABC previously treated with multimodality therapy or MBC\n* Prior treatment for BC in the adjuvant, unresectable locally advanced or metastatic setting must include both: a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent in the adjuvant, unresectable locally advanced or metastatic setting\n* Documented progression of incurable, unresectable LABC or MBC, defined by the investigator: progression must occur during or after most recent treatment for LABC or MBC or within 6 months after completing adjuvant therapy\n* Measurable and/or non-measurable disease, according the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 definition: CNS-only disease excluded\n* Left ventricular ejection fraction (LVEF) \\>/=50% by either echocardiogram or multiple-gated acquisition\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate organ function evidenced by laboratory results within 30 days prior to randomization\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods that result in a failure rate of \\< 1% per year during the treatment period and for at least 7 months after the last dose of study drug\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures (use a condom plus an additional contraceptive method that together result in a failure rate of \\< 1% per year) and agreement to refrain from donating sperm during the treatment period and for at least 7 months after the last dose of study drug\n\nExclusion Criteria:\n\n* History of treatment with trastuzumab emtansine\n* Prior treatment with lapatinib or capecitabine\n* Peripheral neuropathy of Grade \\>/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)\n* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive BC, or cancers with a similar curative outcome as those mentioned above\n* History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization, except hormone therapy which can be given up to 7 days prior to randomization\n* History of radiation therapy within 14 days before randomization\n* Brain metastases that are untreated, symptomatic, progressive, or require therapy such as radiation, surgery or corticosteroid therapy to control symptoms from brain metastases within 30 days before randomization\n* History of exposure to cumulative doses of anthracyclines: Doxorubicin \\> 500 milligrams per square meter (mg/m\\^2), Epirubucin \\> 720 mg/m\\^2, Mitoxantrone \\> 120 mg/m\\^2\n* Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)\n* Pregnancy or lactation\n* Currently known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)\n* Presence of conditions that could affect gastrointestinal absorption\n* History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins\n* Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency\n* Current treatment with sorivudine or its chemically related analogs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}